Category Archives: C. diff. Spores and More Global Broadcasting Network

C. diff. Radio

C. diff. Spores and More, Join Us and Celebrate

www.cdiffradio.com

C. diff. Spores and More

Sponsored by Clorox Healthcare

Join us and Celebrate

with our 81,453 listeners – so far –  in Season III.

We thank our listeners joining us every

Tuesday at 10:00 a.m. PT / 1:00 p.m. ET

across the U.S. A. and to our listeners in

  • Australia
  • Brazil
  • Canada
  • China
  • France
  • Germany
  • India
  • Ireland
  • Israel
  • Japan
  • Malaysia
  • Peru
  • Russia
  • Spain
  • Switzerland
  • Taiwan
  • Trinidad
  • Ukraine
  • UK    and Across the Globe

We also extend our sincere gratitude to the guests who take time out of their busy

schedules to join us on each live broadcast.  Though their words of wisdom and

by sharing the most up-to-date information with us raises awareness in so

many important areas of healthcare.

 

Season III concludes on October 31, 2017

and we will be gearing up for

the 5th Annual International C. diff. Awareness Conference & Health EXPO taking

place on November 9th and 10th at the University of Nevada – Las Vegas.

For conference information please click on the link below.

https://cdifffoundation.org/2017cdiffconference/about-nov-2017-annual-conference/

 

Join us in Season IV when we return on January 9th, 2018

as we continue bringing you updates that are focused on, but not limited to,

C. difficile infection prevention, treatments, clinical trials, environmental safety

and much more.

Thank you again for listening and we wish you and your families improved health,

continued healing, and the best day — which you all deserve!

 

The Latest Developments in C. diff Research and Treatment

 

 

 

 

 

The Program Podcast is Now Available —

Listen at your leisure as our guest, Dr Mary Beth Dorr, PhD, Clinical Director, Clinical Research, Infectious Diseases, and he product development team lead for bezlotoxumab, Merck & Co., Inc.  provided us with an overview of a C. diff. infection, the challenges of recurrence, the latest clinical research overview, current treatment landscape, and pending new C. diff infection treatment guidelines from the Infectious Diseases Society of America (IDSA) that are anticipated to be released fall of 2017.

Click on the C. diff. Spores and More Logo to be connected to the podcast

Medical Mattresses; Healthcare-acquired Infections and How Hospital Bedding Is Involved

Our guests Dr. Edmond Hooker, MD with Bruce Rippe, CEO of Trinity Guardion and  J. Darrel Hicks, BA, Master REH, CHESP joined us on C. diff. Spores and More Global Broadcasting Network live broadcast –August 1st  to  discuss Healthcare – associated Infections (HAIs ) and how they lead to more than 720,000 illnesses and 75,000 deaths a year. In fact, more people die from HAIs each year than from automobile accidents. Furthermore, HAIs are a huge financial burden, adding $30 billion to annual healthcare costs. The American-made Trinity Patient Protection System gives hospitals the solution they need to reduce and eliminate HAIs.

Launderable, reusable, cost-effective and eco-friendly, the Trinity System’s fluid-proof covers fit around beds, pillows, stretchers and physical therapy tables. Unlike typical disinfectant agents designed for hard surfaces, the Trinity System keeps bacteria off the porous surface of the mattress, as well as, the bed deck. When laundered to CDC standards, the Trinity System removes 99.99% of bacteria and has been proven to reduce C. diff infection rates by about 50%.

 

www.trinityguardion.com

 

To learn more, from these leading topic-experts, about Medical Mattress Contamination and how bedding is involved in healthcare-associated infections.

Listen to the podcast available and part of the C.diff. Spores and More living library.

https://www.voiceamerica.com/episode/100501/healthcare-acquired-infections-and-how-hospital-bedding-is-involved

Clifford McDonald, MD and Alison Laufer-Halpin, Ph.D., of the CDC Discuss the Human Microbiome on C. diff. Spores and More

C Diff Foundation’s “C. diff. Spores and More Global Broadcasting Network” is honored to announce Doctors McDonald and Laufer-Halpin as our guest speakers on

Tuesday, July 25, 2017 at 10 a.m. PT / 1 p.m. ET

(www.cdiffradio.com)

These two leading topic experts will be discussing significant ways to unlock the mysteries of the human microbiome; how it affects our health, the immune system, and why it is so important to protect it.

As part of the Centers for Disease Control and Prevention (CDC) efforts to protect patients and slow antibiotic-resistance, the CDC is investing in research to discover and develop new ways to prevent antibiotic-resistant infections.

To Listen To the Podcast – click on the following link:

https://www.voiceamerica.com/episode/100322/the-human-microbiome-how-it-works-how-it-affects-your-health-your-immune-system-and-why-it-is

 

Learn more about C Diff Radio at: http://www.cdiffradio.com/.

Clostridium difficile (C.diff.) a Spore Forming Bacteria

Types of spore forming bacteria.

To provide a background and definition of  each of them the following information is beneficial.

Bacteria are a large group of microscopic, unicellular organisms that exist either independently or as parasites. Some bacteria are capable of forming spores around themselves, which allow the organism to survive in hostile environmental conditions. Bacterial spores are made of a tough outer layer of keratin that is resistant to many chemicals, staining and heat. The spore allows the bacterium to remain dormant for years, protecting it from various traumas, including temperature differences, absence of air, water and nutrients. Spore forming bacteria cause a number of diseases, including botulism, anthrax, tetanus and acute food poisoning. (1)

Bacillus

Bacillus is a specific genus of rod-shaped bacteria that are capable of forming spores. They are sporulating, aerobic and ubiquitous in nature. Bacillus is a fairly large group with many members, including Bacillus cereus, Bacillus clausii and Bacillus halodenitrificans. Bacillus spores, also called endospores, are resistant to harsh chemical and physical conditions. This makes the bacteria able to withstand disinfectants, radiation, desiccation and heat. Bacillus are a common cause of food and medical contamination and are often difficult to eliminate.

Clostridium

Clostridium are rod-shaped, Gram-positive (bacteria that retain a violet or dark blue Gram staining due to excessive amounts of peptidoglycan in their cell walls) bacteria that are capable of producing spores. According to the Health Protecton Agency, the Clostridium genus consists of more than a hundred known species, including harmful pathogens such as Clostridium botulinum, Clostridium difficile, Clostridium perfringens, Clostridium tetani and Clostridium sordellii.

Some species of the bacteria are used commercially to produce ethanol (Clostridium thermocellum), acetone (Clostridium acetobutylicum), and to convert fatty acids to yeasts and propanediol (Clostridium diolis).

Background:

Scientists discovered C. diff in 1935, but they didn’t recognize it as the major cause of antibiotic-associated diarrhea until 1978. The rise of C. diff in the 1970s was triggered by the widespread use of the antibiotic clindamycin. Over the next 20 years, broad-spectrum antibiotics in the penicillin and cephalosporin families fueled the C. diff epidemic, and in the early years of this century, fluoroquinolone antibiotics were linked to a new and more dangerous hypervirulent strain of C. diff.

C. diff is classified as an anaerobic bacterium because it thrives in the absence of oxygen. Like its cousins, the Clostridia that cause tetanus, botulism, and gas gangrene, C. diff passes through a life cycle in which the actively dividing form transforms itself into the spore stage. Spores are inert and metabolically inactive, so they don’t cause disease. At the same time, though, spores are very tough and sturdy; they are hard to kill with disinfectants, and they shrug off even the most powerful antibiotics.

Here’s how C. diff causes trouble. Patients with C. diff shed spores into their feces. Without strict precautions, spores are inadvertently transmitted to hands, utensils, and foods, and then swallowed by someone else. The spores come to life in the second person’s GI tract, but in the best of circumstances, the normal bacteria keep C. diff in check and illness does not develop. But if the “good” GI bacteria have been knocked down by antibiotics, C. diff gets the upper hand. As C. diff multiplies and grows, it produces toxins that injure the lining of the colon, producing diarrhea, inflammation, and sometimes worse. Ordinary strains of C. diff produce two toxins, called toxins A and B, but the new, worrisome hypervirulent strains produce up to 16 times more toxin A and 23 times more toxin B. (2)

C. diff is an old bacterium,…..the CDAD epidemic is new ……..What turned a medical curiosity into a major threat? In a word, antibiotics.

Antibiotics are marvelous medications, and they are obviously here to stay. But doctors must use them wisely. That means prescribing an antibiotic only when it’s truly necessary, choosing the simplest, most narrowly focused drug that will do the job, and stopping treatment as soon as the job is done. Patients can help by resisting the temptation to demand an antibiotic for every potential infection.

When it comes to using antibiotics properly, less can be more.

Sporolactobacillus

Sporolactobacillus is a group of anaerobic, rod-shaped, spore forming bacteria that include Sporolactobacillus dextrus, Sporolactobacillus inulinus, Sporolactobacillus laevis, Sporolactobacillus terrae and Sporolactobacillus vineae. Sporolactobacillus are also known as lactic-acid bacteria for they are capable of producing the acid from fructose, sucrose, raffinose, mannose, inulin and sorbitol. Sporolactobacillus are found in the soil and often in chicken feed. According to “Fundamentals of Food Microbiology,” the spores formed by Sporolactobacillus are less resistant to heat than those formed by the Bacillus genus.

Sporosarcina

Sporosarcina are a group of round-shaped (cocci) aerobic bacteria that include Sporosarcina aquimarina, Sporosarcina globispora, Sporosarcina halophila, Sporosarcina koreensis, Sporosarcina luteola and Sporosarcina ureae. According to “Antibiotic Resistance and Production in Sporosarcina ureae,” Sporosarcina is thought to play a role in the decomposition of urea in the soil.

#########

Revival and Identification of Bacterial Spores in
25- to 40-Million-Year-Old Dominican Amber
Raid J. Cano* and Monica K. Borucki

A bacterial spore was revived, cultured, and identified from the abdominal contents of extinct bees preserved for 25 to 40 million years in buried Dominican amber. Rigorous surface decontamination of the amber and aseptic procedures were used during the recovery of the bacterium. Several lines of evidence indicated that the isolated bacterium was of ancient origin and not an extant contaminant. The characteristic enzymatic, biochemical, and 1 6S ribosomal DNA profiles indicated that the ancient bacterium is most closely related to extant Bacillus sphaericus.

To read the article in its entirety please click on the following link:

http://science.sciencemag.org/content/268/5213/1060.long

 

Sources:

(1)   http://Sciencing.com/types-spore-forming-bacteria-2504.html

(2) http://www.health.harvard.edu/staying-healthy/clostridium-difficile-an-intestinal-infection-on-the-rise

Bridging Collaboration Between Patients and Healthcare Providers to Reduce Hospital-Acquired Infections

cdiffRadioLogoMarch2015

C. diff. Spores and More” Global Broadcasting Network
will host a special episode on their live radio program (cdiffradio.com)
airing on Tuesday, January 24, 2017 at 1:00 pm EST featuring world-renowned
infectious disease expert, Dr. Hudson Garrett Jr., Global Chief Clinical Officer for Pentax Medical-Hoya Corporation and Chairperson of the Clinical Education Committee
for the C Diff Foundation.

This special episode, Bridging Collaboration Between Patients and Healthcare Providers to Reduce Hospital-Acquired Infections (HAI’s),  will feature a robust discussion on the patient’s role in preventing healthcare associated infections, an overview of medical device hygiene and infection control, the importance of antibiotic stewardship, and applications of evidence-based infection control measures across the entire healthcare continuum of care.

“Healthcare continues to become more and more complex as the acuity and needs of the patient changes along with the correlating technologies. Patients and Healthcare Providers must work together to mitigate the risk for Healthcare Associated Infections and other adverse events,” says Dr. Garrett.

C. diff. Spores and More ™“ spotlights world renowned topic experts, research scientists, healthcare professionals, organization representatives, C. diff. survivors, board members, and their volunteers who are all creating positive changes in the
C. diff.
community and more.

Through the interviews, the C Diff Foundation’s mission connects, educates, and empowers listeners worldwide.

Questions received through the show page portal will be reviewed and addressed  by the show’s Medical Correspondent, Dr. Fred Zar, MD, FACP,  Dr. Fred Zar is a Professor of Clinical Medicine, Vice HeZarPhotoWebsiteTop (2)ad for Education in the Department of Medicine, and Program Director of the Internal Medicine Residency at the University of Illinois at Chicago.  Over the last two decades he has been a pioneer in the study of the treatment of Clostridium difficile disease and the need to stratify patients by disease severity.

 

Take our show on the go…………..download a mobile app today

www.voiceamerica.com/company/mobileapps

healthwellnesshealth (2)

Clorox Healthcare, Sponsor of C. diff. Spores and More Global Broadcasting Network

CloroxHealthcare_72

C. diff. Spores and More (cdiffradio.com) Launches Season III

cdiffRadioLogoMarch2015

 

 

 

 

 

Welcome to Season III of C. diff. Spores and More Global Broadcasting Network, and sponsored by Clorox Healthcare (www.cloroxhealthcare.com/cdiffradio)

Join us every Tuesday at 10:00 a.ml PT / 11:00 a.m. MT / 12:00 p.m. CT / 1:00 p.m. ET for our live broadcast.

Dr. Katherine Fleming-Dutra, MD is a medical epidemiologist with the Office of Antibiotic Stewardship in the Division of Healthcare Quality Promotion at the Centers for Disease Control and Prevention (CDC).  Dr. Fleming-Dutra is a Pediatrician and Pediatric Emergency Medicine physician and has focused on infectious diseases, epidemiology, and antibiotic stewardship in the outpatient setting in her career at the CDC.

Dr. Fleming-Dutra spent an hour with us discussing the Over Prescribing Of Antibiotics   —  and the Key to Fighting Antibiotic-Resistance — clinicians and patients.

https://www.voiceamerica.com/episode/96728/a-prescription-for-over-prescribing-the-key-to-fighting-antibiotic-resistance

The guidelines, programs, campaigns, tracking methods, and tools being provided by the CDC are outstanding and need to be shared and implemented by clinicians to continue reducing the rate by 50% by 2020 of all inappropriate selections and incorrect duration in antibiotic therapies.  Antibiotic Stewardship programs are available and should be in place across the healthcare industry.

Antibiotic Stewardship Guidelines

For Healthcare Providers and Professionals:  To learn more about the outstanding tools provided by the CDC  to aid in bringing about positive changes please click on the links provided below:

Here are links to the Core Elements:

https://www.cdc.gov/getsmart/community/improving-prescribing/core-elements/core-outpatient-stewardship.html

https://www.cdc.gov/getsmart/healthcare/implementation/core-elements.html

https://www.cdc.gov/longtermcare/prevention/antibiotic-stewardship.html

 AND

Links to Patient Safety Atlas

Antibiotic Resistance Patient Safety Atlas: Outpatient Antibiotic Prescriptions by State Data (2011-2014)

Antibiotic Resistance Patient Safety Atlas: Healthcare Facilities Reporting HAIs by State Data (2011-2014)

https://www.voiceamerica.com/episode/96728/a-prescription-for-over-prescribing-the-key-to-fighting-antibiotic-resistance

We know that the CDC’s most recent figure for C. difficile-associated deaths in the U.S. is considerably higher than that of any previous survey. According to the CDC*

  • Nearly 500,000 patients are diagnosed with a C. diff infection estimated per year in the U.S., with more than 29,000 deaths
  • Up to $4.8 billion in excess health care costs for acute care facilities
  • Prevention steps include antibiotic stewardship and improved infection control in hospitals, doctor’s offices, nursing homes and other healthcare facilities

C. diff. Spores and More ™“ spotlights world renowned topic experts, research scientists, healthcare professionals, organization representatives, C. diff. survivors, board members, and their volunteers who are all creating positive changes in the
C. diff.
community and worldwide.

Through interviews – each episode becomes part of the living library.  The podcasts are accessed continuously promoting education and advocating the C Diff Foundation’s mission that are connecting, educating, and empowering listeners worldwide.

Questions received through the show page portal will be reviewed and addressed  by the show’s Medical Correspondent, Dr. Fred Zar, MD, FACP,  Dr. Fred Zar is a Professor of Clinical Medicine, Vice HeZarPhotoWebsiteTop (2)ad for Education in the Department of Medicine, and Program Director of the Internal Medicine Residency at the University of Illinois at Chicago.  Over the last two decades he has been a pioneer in the study of the treatment of Clostridium difficile disease and the need to stratify patients by disease severity.

Take our program on the go…………..download a mobile app today

www.voiceamerica.com/company/mobileapps

healthwellnesshealth (2)